[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100187675":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":28,"centralContacts":27,"locations":32,"responsibleParty":43,"collaborators":27,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":27,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":27,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":27,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Canagliflozin + cyclosporine","EXPERIMENTAL","Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.",[13,14],"Drug: Canagliflozin (JNJ-28431754)","Drug: Cyclosporine",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Canagliflozin (JNJ-28431754)","One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.",[9],[22],"JNJ-28431754",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Cyclosporine","Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.",[9],null,[29],{"name":30,"affiliation":5,"role":31},"Johnson & Johnson Pharmaceutical Research & Development,L.L. C. Clinical Trial","STUDY_DIRECTOR",[33],{"facility":27,"status":27,"city":34,"state":27,"zip":27,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":27},"Antwerp","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],4.40026,51.22047,{"lat":41,"lon":40},{"type":44,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100187675","phase-1-a-study-to-assess-the-effects-of-cyclosporine-on-the-pharmacokinetics-and-safety-of-canagliflozin-jnj-28431754-in-healthy-volunteers-100187675",false,"NCT01718652","A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers","An Open-Label, Single Sequence Study to Assess the Effect of a Single Dose of Cyclosporine on the Steady-State Pharmacokinetics of JNJ-28431754 (Canagliflozin) in Healthy Adult Subjects","Inclusion Criteria:\n\n* Must have body mass index between 18 and 30 kg\u002Fm2 (inclusive), and body weight not less than 50 kg\n* If a woman, must be either postmenopausal, defined as no spontaneous menses for at least 18 months or amenorrhea for at least 6 months or surgically sterile (have had a hysterectomy, or tubal ligation)\n\nExclusion Criteria:\n\n* History of smoking or use of nicotine-containing substances within the previous 2 months\n* Have had history of or current medical illness considered to be clinically significant by the Investigator",true,"ALL","18 Years","55 Years",{"count":57,"type":58},18,"ACTUAL","INTERVENTIONAL",[61],"PHASE1","The purpose of this study is to determine how a single dose of cyclosporin affects the pharmacokinetics (ie, how the body affects the drug) of multiple doses of canagliflozin (JNJ-28431754). The safety and tolerability of canagliflozin will also be assessed in healthy volunteers.",[64],"Healthy",[64,18,66,24],"Pharmacokinetics","COMPLETED","2012-11-22",{"date":70,"type":71},"2012-11-27","ESTIMATED",{"date":73,"type":27},"2011-02",{"date":75,"type":58},"2011-04",{"name":5,"class":6},1]